Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women

D. M. Kim, S. J. Yoon, C. W. Ahn, B. S. Cha, S. K. Lim, K. R. Kim, H. C. Lee, K. B. Huh

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The aim of this study was to evaluate the effects of sibutramine on body composition and fat distribution, insulin resistance, and serum adiponectin levels in obese women. A total of 28 obese, premenopausal women (mean age, 34.5 ± 13.7 years; BMI, 31.00 ± 4.10 kg/m2) was studied before and after 12-week-course of sibutramine (10 mg/day). Sibutramine treatment reduced body mass index (P < 0.05) and total body fat (P < 0.05). Abdominal subcutaneous and visceral fat areas (ASFA and AVFA) and mid-thigh low density muscle areas (LDMA) measured by computed-tomography decreased significantly (all, P < 0.05). Insulin resistance (IR) calculated from the homeostasis model assessment (HOMA) method decreased (P < 0.05) and serum adiponectin levels increased significantly (P < 0.05). In our sequential data, the changes of fasting serum insulin levels and the HOMA-IR scores, serum free fatty acids and triglyceride levels, serum adiponectin levels and the mid-thigh LDMA preceded significant changes of body weight, total body fat, and abdominal fat distribution, suggesting sibutramine might improve insulin sensitivity directly by alterations of fatty acid metabolism or secondarily by increasing serum adiponectin levels. Conclusively, sibutramine improved fat distribution and insulin resistance, and increased serum adiponectin levels in Korean obese nondiabetic premenopausal women.

Original languageEnglish
Pages (from-to)S139-S144
JournalDiabetes Research and Clinical Practice
Volume66
Issue numberSUPPL.
DOIs
Publication statusPublished - 2004 Dec 1

Fingerprint

sibutramine
Adiponectin
Insulin Resistance
Fats
Serum
Thigh
Adipose Tissue
Homeostasis
Abdominal Subcutaneous Fat
Body Fat Distribution
Muscles
Abdominal Fat
Body Weight Changes
Intra-Abdominal Fat
Body Composition
Nonesterified Fatty Acids

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Kim, D. M. ; Yoon, S. J. ; Ahn, C. W. ; Cha, B. S. ; Lim, S. K. ; Kim, K. R. ; Lee, H. C. ; Huh, K. B. / Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women. In: Diabetes Research and Clinical Practice. 2004 ; Vol. 66, No. SUPPL. pp. S139-S144.
@article{2a16a2d6728f4ff8930bc544ad09b8c3,
title = "Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women",
abstract = "The aim of this study was to evaluate the effects of sibutramine on body composition and fat distribution, insulin resistance, and serum adiponectin levels in obese women. A total of 28 obese, premenopausal women (mean age, 34.5 ± 13.7 years; BMI, 31.00 ± 4.10 kg/m2) was studied before and after 12-week-course of sibutramine (10 mg/day). Sibutramine treatment reduced body mass index (P < 0.05) and total body fat (P < 0.05). Abdominal subcutaneous and visceral fat areas (ASFA and AVFA) and mid-thigh low density muscle areas (LDMA) measured by computed-tomography decreased significantly (all, P < 0.05). Insulin resistance (IR) calculated from the homeostasis model assessment (HOMA) method decreased (P < 0.05) and serum adiponectin levels increased significantly (P < 0.05). In our sequential data, the changes of fasting serum insulin levels and the HOMA-IR scores, serum free fatty acids and triglyceride levels, serum adiponectin levels and the mid-thigh LDMA preceded significant changes of body weight, total body fat, and abdominal fat distribution, suggesting sibutramine might improve insulin sensitivity directly by alterations of fatty acid metabolism or secondarily by increasing serum adiponectin levels. Conclusively, sibutramine improved fat distribution and insulin resistance, and increased serum adiponectin levels in Korean obese nondiabetic premenopausal women.",
author = "Kim, {D. M.} and Yoon, {S. J.} and Ahn, {C. W.} and Cha, {B. S.} and Lim, {S. K.} and Kim, {K. R.} and Lee, {H. C.} and Huh, {K. B.}",
year = "2004",
month = "12",
day = "1",
doi = "10.1016/j.diabres.2003.12.008",
language = "English",
volume = "66",
pages = "S139--S144",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL.",

}

Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women. / Kim, D. M.; Yoon, S. J.; Ahn, C. W.; Cha, B. S.; Lim, S. K.; Kim, K. R.; Lee, H. C.; Huh, K. B.

In: Diabetes Research and Clinical Practice, Vol. 66, No. SUPPL., 01.12.2004, p. S139-S144.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women

AU - Kim, D. M.

AU - Yoon, S. J.

AU - Ahn, C. W.

AU - Cha, B. S.

AU - Lim, S. K.

AU - Kim, K. R.

AU - Lee, H. C.

AU - Huh, K. B.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - The aim of this study was to evaluate the effects of sibutramine on body composition and fat distribution, insulin resistance, and serum adiponectin levels in obese women. A total of 28 obese, premenopausal women (mean age, 34.5 ± 13.7 years; BMI, 31.00 ± 4.10 kg/m2) was studied before and after 12-week-course of sibutramine (10 mg/day). Sibutramine treatment reduced body mass index (P < 0.05) and total body fat (P < 0.05). Abdominal subcutaneous and visceral fat areas (ASFA and AVFA) and mid-thigh low density muscle areas (LDMA) measured by computed-tomography decreased significantly (all, P < 0.05). Insulin resistance (IR) calculated from the homeostasis model assessment (HOMA) method decreased (P < 0.05) and serum adiponectin levels increased significantly (P < 0.05). In our sequential data, the changes of fasting serum insulin levels and the HOMA-IR scores, serum free fatty acids and triglyceride levels, serum adiponectin levels and the mid-thigh LDMA preceded significant changes of body weight, total body fat, and abdominal fat distribution, suggesting sibutramine might improve insulin sensitivity directly by alterations of fatty acid metabolism or secondarily by increasing serum adiponectin levels. Conclusively, sibutramine improved fat distribution and insulin resistance, and increased serum adiponectin levels in Korean obese nondiabetic premenopausal women.

AB - The aim of this study was to evaluate the effects of sibutramine on body composition and fat distribution, insulin resistance, and serum adiponectin levels in obese women. A total of 28 obese, premenopausal women (mean age, 34.5 ± 13.7 years; BMI, 31.00 ± 4.10 kg/m2) was studied before and after 12-week-course of sibutramine (10 mg/day). Sibutramine treatment reduced body mass index (P < 0.05) and total body fat (P < 0.05). Abdominal subcutaneous and visceral fat areas (ASFA and AVFA) and mid-thigh low density muscle areas (LDMA) measured by computed-tomography decreased significantly (all, P < 0.05). Insulin resistance (IR) calculated from the homeostasis model assessment (HOMA) method decreased (P < 0.05) and serum adiponectin levels increased significantly (P < 0.05). In our sequential data, the changes of fasting serum insulin levels and the HOMA-IR scores, serum free fatty acids and triglyceride levels, serum adiponectin levels and the mid-thigh LDMA preceded significant changes of body weight, total body fat, and abdominal fat distribution, suggesting sibutramine might improve insulin sensitivity directly by alterations of fatty acid metabolism or secondarily by increasing serum adiponectin levels. Conclusively, sibutramine improved fat distribution and insulin resistance, and increased serum adiponectin levels in Korean obese nondiabetic premenopausal women.

UR - http://www.scopus.com/inward/record.url?scp=9644289526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9644289526&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2003.12.008

DO - 10.1016/j.diabres.2003.12.008

M3 - Article

C2 - 15563965

AN - SCOPUS:9644289526

VL - 66

SP - S139-S144

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - SUPPL.

ER -